Search | Clinical Trials Finder

Conditions: Hypotension
Interventions: Colloid administration, Crystalloid administration, phenylephrine infusion; Other · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Acne Vulgaris
Interventions: Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo; Drug
Lead sponsor: Aleor Dermaceuticals Limited; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more

Conditions: Abscess
Interventions: Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage; Drug · Device · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Verruca Vulgaris, Common Warts
Interventions: ingenol mebutate 0.05% gel; Drug
Lead sponsor: Neal D. Bhatia, MD; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hemangioma
Interventions: timolol maleate 0.5% gel; Drug
Lead sponsor: Rady Children's Hospital, San Diego; Other
Eligibility: 7 Days to 6 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Dystrophic Epidermolysis Bullosa
Interventions: PTW-002 10 mg/g gel, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 4 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Head and Neck Cancer, Radiation Dermatitis
Interventions: KeraStat Cream, Routine Skin Care - Commercially Available Agents; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Wound Heal
Interventions: MAP Wound Matrix, DuoDerm; Device
Lead sponsor: Tempo Therapeutics; Industry
Eligibility: 22 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Encino, California • Indianapolis, Indiana • Cypress, Texas

Conditions: Metastatic Liver Carcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer
Interventions: Angiography, Computed Tomography, Planar Imaging, Radioembolization, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Yttrium Y 90 Resin Microspheres; Procedure · Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acne Vulgaris
Interventions: Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.), Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd); Drug · Other
Lead sponsor: Torrent Pharmaceuticals Limited; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Sherman Oaks, California • Brandon, Florida • Miami, Florida + 7 more

Conditions: Rectal Microbicides
Interventions: Tenofovir 1% gel, 2% N-9 gel, HEC Placebo gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Venus Leg Ulcers
Interventions: EscharEx (EX-03), Placebo (Gel vehicle); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Covid19
Interventions: hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule); Biological · Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: El Segundo, California • Newport Beach, California

Conditions: Colorectal Cancer, Head and Neck Cancer
Interventions: Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid); Drug · Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Modified Barium Swallow, Paclitaxel, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography, Technetium Tc 99m-labeled Tilmanocept, Technetium Tc-99m Sulfur Colloid; Procedure · Drug · Other + 1 more
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Seasonal Allergic Rhinitis, SAR
Interventions: BDP HFA, Placebo nasal aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more

Conditions: Psoriasis Vulgaris
Interventions: PTH (1-34) Gel / Placebo Gel; Drug
Lead sponsor: Manhattan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: San Diego, California • Ormond Beach, Florida • Fridley, Minnesota + 1 more

Conditions: Actinic Keratoses
Interventions: Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo; Drug · Other
Lead sponsor: Encube Ethicals Pvt. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 24
States / cities: Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more

Conditions: Advanced Malignant Neoplasm
Interventions: Fat Emulsion, Placebo; Dietary Supplement · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Interventions: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension; Drug
Lead sponsor: NanOlogy, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Gainesville, Florida • Fort Wayne, Indiana • Baltimore, Maryland + 1 more

Conditions: Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug; Procedure · Drug
Lead sponsor: Retina Vitreous Associates of Florida; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Congenital Venous Malformation
Interventions: Ethanol 96% Gel, Ethanol 98% Solution; Drug
Lead sponsor: Orfagen; Industry
Eligibility: 12 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Adenocarcinoma, Prostatic Neoplasm, Urogenital Neoplasms, Genital Neoplasms, Male, Localized Cancer
Interventions: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension; Drug
Lead sponsor: NanOlogy, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Tampa, Florida • Kansas City, Kansas • Detroit, Michigan + 1 more

Conditions: HIV/AIDS
Interventions: Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV); Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Spinal Anesthesia Induced Hypotension During Cesarean Section

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy

Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds.

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin

Trial of NanoPac Intratumoral Injection in Lung Cancer

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.

Trial of NanoPac Focal Therapy for Prostate Cancer

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults